Cellectar Biosciences (CLRB) risk factors

45 risks, 5 new, 7 dropped, 6 reworded since the prior year. The company added disclosures on supplier dependencies, EU drug legislation reforms, and stock price compliance. Financial restatement disclosures were expanded to cover additional quarters. Nasdaq minimum stockholders' equity requirements were added to listing risks.

47 risks. Operating cash of $23.3 million funds operations only into the fourth quarter of 2025. Financial statement restatements for 2022 and 2023 expose the company to legal and regulatory risks. Dependence on third-party contract research organizations and outsourced manufacturing creates operational vulnerabilities.